NewAmsterdam Pharma (NAMS) Total Current Liabilities (2022 - 2025)
Historic Total Current Liabilities for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $58.3 million.
- NewAmsterdam Pharma's Total Current Liabilities rose 4124.83% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year increase of 4124.83%. This contributed to the annual value of $106.9 million for FY2024, which is 11427.74% up from last year.
- NewAmsterdam Pharma's Total Current Liabilities amounted to $58.3 million in Q3 2025, which was up 4124.83% from $36.5 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Total Current Liabilities registered a high of $106.9 million during Q4 2024, and its lowest value of $36.2 million during Q4 2022.
- Moreover, its 4-year median value for Total Current Liabilities was $43.5 million (2023), whereas its average is $51.7 million.
- In the last 5 years, NewAmsterdam Pharma's Total Current Liabilities surged by 11427.74% in 2024 and then plummeted by 3149.88% in 2025.
- Over the past 4 years, NewAmsterdam Pharma's Total Current Liabilities (Quarter) stood at $36.2 million in 2022, then surged by 37.92% to $49.9 million in 2023, then skyrocketed by 114.28% to $106.9 million in 2024, then crashed by 45.5% to $58.3 million in 2025.
- Its Total Current Liabilities stands at $58.3 million for Q3 2025, versus $36.5 million for Q2 2025 and $40.9 million for Q1 2025.